Antibody Research

Immunization of transgenic animals producing human antibodies is the most successful approach to obtaining fully human therapeutic antibodies. They allow for the rapid generation of candidate antibodies and the ability to transition lead candidates to clinical development without undergoing time-consuming steps such as the humanization of murine antibodies or the affinity maturation of antibodies from structural display libraries.

Hybridoma cell lines have historically offered an efficient, low-cost means to produce large numbers of monoclonal antibodies. However, there are reasons that warrant recombinantly expressing an antibody at a preclinical, R&D stage. These reasons include the need to express antibodies from primary B cells, a surface display library, convert chimeric antibodies to fully human antibodies, humanization of rodent antibodies, and isotype switching. We have developed a recombinant expression system for drug discovery with the ability to express a large number of recombinant antibodies in a timely, cost-efficient manner.